Nontuberculous Mycobacterial Infection Market Forecast Reaching $19.57 Billion by 2029 at 6.7% CAGR
Discover trends, market shifts, and competitive outlooks for the nontuberculous mycobacterial infection industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Projections for the CAGR of the Nontuberculous Mycobacterial Infection Market Size From 2025 to 2034?
The market size for nontuberculous mycobacterial infection has seen robust growth in recent times. The growth is projected to escalate from $14.25 billion in 2024 to $15.11 billion in 2025, marking a compound annual growth rate (CAGR) of 6.0%. The progress during the historic period can be ascribed to advancements in diagnostics, an increasing aging population, heightened awareness of cystic fibrosis, and the use of immunosuppressive drugs.
The market for nontuberculous mycobacterial infection is predicted to experience substantial growth in the coming years. It is anticipated to reach a value of $19.57 billion by 2029, with a compound annual growth rate of 6.7%. Elements contributing to this growth throughout the projected period include the development of antimicrobial drugs, increasing awareness about ntm, advancements in genetic research, and the rise of telehealth and remote monitoring. Key trends for this period encompass personalized treatment plans, regulatory focus, combination therapies, as well as digital health tools.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Nontuberculous Mycobacterial Infection Market?
The increasing incidence of chronic obstructive pulmonary disease (COPD) is anticipated to drive the nontuberculous mycobacterial infection market’s expansion. COPD is a long-term respiratory disease marked by continuous and often increasing limitations on airflow within the lungs. The damage caused to the lung tissue by COPD and the weakening of the immune system make it simpler for nontuberculous mycobacterial (NTM) infections to invade the lungs. Notably, patients with COPD who also have NTM infections present a more notable decrease in their forced expiratory volume in one second (FEV1) and a higher rate of exacerbation. As highlighted by The Scottish Public Health Observatory (ScotPHO) in March 2023, COPD rates have begun to increase between 2021 and 2022, with male rates escalating from 83.2 to 97.6 per 100,000 individuals, and female rates increasing from 72.6 to 97.3. Consequently, the rising rate of chronic obstructive pulmonary disease (COPD) is propelling the nontuberculous mycobacterial infection market. An upsurge in the prevalence of infectious diseases is predicted to fuel the growth of the nontuberculous mycobacterial infection market. Infectious diseases are pathological conditions provoked by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, which can transmit from one person to another. Notably, conditions that could potentially lead to Nontuberculous Mycobacterial (NTM) infections also contribute to the rising prevalence of infectious diseases. This spurs the growth of the NTM infection market by increasing awareness, encouraging more frequent diagnostic procedures and early detection, amplifying research and development endeavors for NTM treatments, and creating larger demand for therapies aimed at NTM pathogens due to increased emphasis on infectious diseases within healthcare. According to UNICEF in November 2024, pneumonia was the top infectious disease causing over 700,000 child deaths per year, corresponding to around 2,000 children each day. Hence, the heightened incidence of infectious diseases boosts the growth of the nontuberculous mycobacterial infection market.
Which Key Market Segments Comprise the Nontuberculous Mycobacterial Infection Market and Drive Its Revenue Growth?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp
Which Areas Are Leading Regions in the Nontuberculous Mycobacterial Infection Market Expansion Across the Globe?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Market Trends in theNontuberculous Mycobacterial Infection Market Over the Coming Years?
Primary organizations in the nontuberculous mycobacterial infection market have adopted new methodologies for treatment approval, such as the Fast Track designation, to maintain their market presence. The FDA has set up a process known as Fast Track designation to hasten the growth and evaluation of medications for serious conditions lacking sufficient medical solutions. For instance, in July 2022, the Food and Drug Administration, a government agency in the U.S., authorized NUZYRA with Fast Track Designation to cure nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), a unique broad-spectrum antibiotic, was developed to fight severe bacterial infections, including those triggered by resistant varieties. This designation ensures a swift advancement and assessment process for NUZYRA antibiotic in order to address significant unmet medical needs.
View the full report here:
How Is the Nontuberculous Mycobacterial Infection Market Conceptually Defined?
A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
